Judith Cassidy
Psychiatric/Mental Health · Hammonton, NJNPI 1790365849
Payments from drug & device makers
Across 220 payments — averaging $21.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$931
- Teva Pharmaceuticals USA, Inc.$861
- Alkermes, Inc.$773
- Neurocrine Biosciences, Inc.$642
- E.r. Squibb & Sons, L.L.C.$498
- Otsuka America Pharmaceutical, Inc.$466
- plus $546 from 4 others
What the payments were for
- Food & beverage$4,57097%
- Education$1473%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 34 | $931 |
| Teva Pharmaceuticals USA, Inc. | 46 | $861 |
| Alkermes, Inc. | 45 | $773 |
| Neurocrine Biosciences, Inc. | 35 | $642 |
| E.r. Squibb & Sons, L.L.C. | 20 | $498 |
| Otsuka America Pharmaceutical, Inc. | 20 | $466 |
| Braeburn Inc. | 5 | $268 |
| Johnson & Johnson | 9 | $178 |
| Lundbeck LLC | 3 | $55 |
| Indivior Inc. | 3 | $45 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,717 in reported general payments places this provider in the 90th percentile of 1,212 psychiatric/mental health providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 16 | $131,565 |
| Invega SustennaPaliperidone Palmitate | 30 | $105,460 |
| PerserisRisperidone | 20 | $54,574 |
| Abilify MaintenaAripiprazole | 15 | $54,355 |
| RexultiBrexpiprazole | 19 | $29,387 |
| VivitrolNaltrexone Microspheres | 12 | $19,237 |
| Risperidone ErRisperidone Microspheres | 16 | $18,671 |
| LybalviOlanzapine/Samidorphan Malate | 11 | $17,526 |
| Aripiprazole | 85 | $9,888 |
| Lamotrigine ErLamotrigine | 13 | $4,115 |
| Haloperidol | 57 | $1,985 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 40 | $1,779 |
| Benztropine Mesylate | 101 | $1,561 |
| Olanzapine | 52 | $1,523 |
| Clozapine | 16 | $945 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $642 | $131,56516 claims |
| Johnson & JohnsonInvega Sustenna | $178 | $105,46030 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $466 | $83,74234 claims |
| Indivior Inc.Perseris | $45 | $54,57420 claims |
| Alkermes, Inc.Vivitrol, Lybalvi | $773 | $36,76323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,212 psychiatric/mental health providers in New Jersey.
Other psychiatric/mental health in Hammonton
- Ubong UdofiaMarlton$407K
- Anthony DimuraRed Bank$130K
- Amy PinsenNewton$111K
- Aaron SpectorMarlton$100K
- Fiorella ParadisiSparta$84K
- Diane BurtBridgeton$81K
- Alta ManessHackensack$75K
- Laura LeahySewell$41K
- Linda WinfulMontclair$40K
- Marisa SavicOradel$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.